Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Kasper

Showing results (51-60 of 199) with videos related to

Pageof 20
Sort By:
European Journal of Pharmacology|November 3, 1995
Effects of semotiadil, a novel Ca2+ channel antagonist, on the electrical activity of Langendorff-perfused guinea pig hearts in comparison with diltiazem, amlodipine and nifedipineG Stark, K Kasper, U Stark, et al.
Blood|August 1, 1986
Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrationsM H Rosove, M Ismail, B J Koziol, et al.
Annals of Internal Medicine|July 1, 1985
Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressinB de la Fuente, C K Kasper, F R Rickles, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 12, 1999
Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacementH A Liebman, T Rosenwald-Zuckerman, A Retzios, et al.
The Biochemical Journal|January 1, 1990
Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteinsS G Spitzer, B J Warn-Cramer, C K Kasper, et al.
Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft|July 9, 2008
[Autologous serum and alternative blood products for the treatment of ocular surface disorders]G Geerling, J D Unterlauft, K Kasper, et al.
Seminars in Hematology|April 1, 1993
Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitorsJ N Lozier, E Santagostino, C K Kasper, et al.
Pacing and Clinical Electrophysiology : PACE|February 1, 1996
How to measure AV nodal refractoriness in the presence of verapamil, amiodarone, digoxin, and diltiazemG Stark, K Kasper, C Schulze-Bauer, et al.
American Journal of Hematology|May 1, 1995
Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study GroupI Warrier, C K Kasper, G C White, et al.
Genomics|February 1, 1990
Use of denaturing gradient gel electrophoresis to detect point mutations in the factor VIII geneM D Traystman, M Higuchi, C K Kasper, et al.
Pageof 20

Showing results (51-60 of 199) with videos related to

Sort By:
Pageof 20
European Journal of Pharmacology|November 3, 1995
Effects of semotiadil, a novel Ca2+ channel antagonist, on the electrical activity of Langendorff-perfused guinea pig hearts in comparison with diltiazem, amlodipine and nifedipineG Stark, K Kasper, U Stark, et al.
Blood|August 1, 1986
Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrationsM H Rosove, M Ismail, B J Koziol, et al.
Annals of Internal Medicine|July 1, 1985
Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressinB de la Fuente, C K Kasper, F R Rickles, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 12, 1999
Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacementH A Liebman, T Rosenwald-Zuckerman, A Retzios, et al.
The Biochemical Journal|January 1, 1990
Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteinsS G Spitzer, B J Warn-Cramer, C K Kasper, et al.
Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft|July 9, 2008
[Autologous serum and alternative blood products for the treatment of ocular surface disorders]G Geerling, J D Unterlauft, K Kasper, et al.
Seminars in Hematology|April 1, 1993
Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitorsJ N Lozier, E Santagostino, C K Kasper, et al.
Pacing and Clinical Electrophysiology : PACE|February 1, 1996
How to measure AV nodal refractoriness in the presence of verapamil, amiodarone, digoxin, and diltiazemG Stark, K Kasper, C Schulze-Bauer, et al.
American Journal of Hematology|May 1, 1995
Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study GroupI Warrier, C K Kasper, G C White, et al.
Genomics|February 1, 1990
Use of denaturing gradient gel electrophoresis to detect point mutations in the factor VIII geneM D Traystman, M Higuchi, C K Kasper, et al.
Pageof 20